NIH-funded research R21 grant

Restoring small-intestine bile acids to prevent antibiotic-related gut imbalance

Official title: Alleviating antibiotic-induced gut dysbiosis by restoring small intestinal bile acid metabolism

Funded at Brown University · NIH-11229642 · Data updated 2026-11-12

Researchers will try restoring how the small intestine handles bile acids to help protect gut bacteria in people taking antibiotics like amoxicillin.

More Dysbiosis research and trials

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionBrown University
NIH-funded
Lab location1 site (Providence, United States)
Project startNovember 8, 2024
Project endOctober 31, 2026
Funding year2026
Award (this year)$199,375
NIH project number5R21AI183146-02
Project IDNIH-11229642 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates would be people who are taking or scheduled to take broad-spectrum antibiotics such as amoxicillin and are willing to provide samples or attend study visits.

Less likely to help

People not exposed to antibiotics or whose gut problems are caused by other conditions (for example, chronic inflammatory bowel disease unrelated to recent antibiotics) may not benefit from this approach.

What this research studies

Antibiotics can upset the mix of helpful bacteria in the gut, causing short- and long-term problems. This project focuses on bile acids made by the body in the small intestine, which help shape which microbes survive farther down in the gut. The team will measure how antibiotics change small-intestine bile acid processing and microbiome composition and test ways to restore normal bile acid metabolism using lab models and clinical samples. Their work aims to find approaches that could be given alongside antibiotics to keep the gut microbiome balanced.

Why it matters

Potential benefit: If successful, this could reduce antibiotic-related gut disturbances and lower the risk of complications from microbiome disruption.

How similar studies have gone: Previous research has shown antibiotics disrupt fecal microbiota and some bile-acid–based approaches look promising in early lab or animal work, but targeting small-intestine bile acid metabolism in humans is relatively new.

Where this research is happening

  • Brown University
    Providence, United States
    Active

Researchers

  • Principal investigator: Belenky, Peter — Brown University
  • Study coordinator: Belenky, Peter

Related research

Other NIH-funded projects on the same topics.

  • Microbial Dysbiosis and Its Role in Pancreatic Cancer

    A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.

    NIH research Northwestern University · Chicago, United States · NIH-11624054

  • From Symbiosis to Dysbiosis: How Resolving Inflammation Could Restore Your Mouth’s Balance

    This grant explores how turning off the harmful inflammation in periodontitis and promoting natural healing could help restore the mouth’s healthy balance.

    NIH research Ada Forsyth Institute, INC. · Somerville, UNITED STATES · NIH-11621747

  • Antibiotics, gut health, and skin reactions in kids

    A small study in children will look at whether antibiotic use and gut bacteria play a role in hives and related symptoms that children sometimes get after antibiotics.

    NIH research Cincinnati Childrens Hosp Med Ctr · Cincinnati, United States · NIH-11603169

  • Novel therapeutic to protect the gut after radiation

    A new GI-directed treatment given after radiation exposure may reduce gut damage and improve survival in people exposed to high-dose radiation.

    NIH research Columbia University Health Sciences · New York, United States · NIH-11572662

  • A new GI-focused treatment to reduce radiation damage after exposure

    A potential GI-targeted therapy given after radiation exposure may help protect the gut and improve survival in people affected by radiation injuries.

    NIH research Columbia University Health Sciences · New York, United States · NIH-11572658

  • How a mouth bacterium might fuel gum disease and heart risk

    A small study will look at how a bacterium in the mouth that makes a reactive chemical (methylglyoxal) could drive gum inflammation and changes in the mouth’s bacteria, possibly linking to heart disease.

    NIH research State University of New York at Buffalo · Amherst, United States · NIH-11564245

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.